Safety & Efficacy Evaluation of a Radiofrequency & Laser/Light System for Improvement of Skin Texture

Exclusion Criteria

• •1. Pregnant or intending to become pregnant during the course of study. A urine pregnancy test will be given to women of childbearing potential and performed during initial visit;
• •2. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator
• •3. Having a permanent implant in the treated area, such as metal plates and screws
• •4. Unable or unlikely to refrain from tanning, including the use of tanning booths, during the course of the study
• •5. Prior use of retinoids in treated area within 2 weeks of initial treatment or during the course of the study
• •6. Use of oral Isotretinoin (Accutane®) within 6 months of initial treatment or during the course of the study
• •7. Patient on systemic corticosteroid therapy 6 months prior to and throughout the course of the study
• •8. Having received a facial dermabrasion or chemical peel treatment within 3 months of treatment or during the study
• •9. Prior skin treatment with laser in treated area within 3 months of initial treatment or during the course of the study
• •10. Prior use of Botox, collagen, fat injections and /or other methods of skin augmentation (enhancement with injected or implanted material) in treated area within 3-4 weeks of initial treatment or during the course of the study. Treatment may not be performed at all over permanent dermal implants
• •11. Prior ablative resurfacing procedure, brow lift, blepharoplasty or face lift in treated area with laser or other devices within 12 months of initial treatment or during the course of the study
• •12. Any other surgery in treated area within 12 months of initial treatment or during the course of the study
• •13. History of keloid formation or poor wound healing in a previously injured skin area
• •14. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity)
• •15. Open laceration or abrasion of any sort on the area to be treated
• •16. Active Herpes Simplex I at the time of treatment
• •17. Multiple dysplastic nevi in the area to be treated
• •18. Having a bleeding disorder or taking anticoagulation medications, including heavy use of aspirin, in a manner which does not allow for a minimum 10 day washout period prior to the treatment (as per the subject 's physician discretion)
• •19. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications
• •20. Having any form of active cancer at the time of enrollment and during the course of the study
• •21. Significant concurrent illness, such as uncontrolled diabetes i.e. any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process
• •22. Participation in a study of another device or drug within 1 month prior to study enrollment or during this study, and as per the Investigator's careful discretion, as long as not contradictory to any of the above criteria
• •23. Tattoos, including cosmetic make-up tattoos, in the treatment area
• •24. Mentally incompetent, prisoner or evidence of active substance or alcohol abuse
• •25. Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research